Get the Daily Brief
Latest Biotech News
Colossal buys Viagen to add cloning, biobank muscle
Colossal Biosciences acquired Viagen Pets & Equine, a cloning and biobanking specialist, integrating Viagen’s reproductive and preservation capabilities into Colossal’s broader...
Nautilus installs single‑molecule proteomics platform at Buck Institute
Nautilus Biotechnology placed its single‑molecule protein analysis system at the Buck Institute for Research on Aging—the first external installation—so Buck researchers can profile tau...
Exact Sciences posts strong quarter as screening climbs
Exact Sciences reported third‑quarter revenues of $850.7 million, a 20% increase year‑over‑year, driven by growth in its Cologuard screening business and rising precision oncology...
UniQure’s Huntington bid stalls: FDA backs away from external‑control path
UniQure said the U.S. Food and Drug Administration signaled that data from its phase I/II AMT‑130 program compared with an external control group may not be adequate to support a biologics license...
FDA drug leadership in turmoil: CDER left helmless after Tidmarsh exit
George Tidmarsh resigned as director of the FDA’s Center for Drug Evaluation and Research after being placed on administrative leave amid an HHS probe into his conduct. The departure leaves CDER...
Sarepta’s Duchenne confirmatory miss: company vows to press FDA for full approvals
Sarepta reported that its long‑awaited confirmatory ESSENCE Phase III trial of exon‑skipping antisense oligonucleotides failed to meet the primary endpoint, sending its shares sharply lower. The...
Metsera takeover melee: Novo ups bid to $10B as Pfizer pushes back
Novo Nordisk raised its offer for obesity biotech Metsera to as much as $10 billion, topping Pfizer’s competing bid and escalating a weeks‑long acquisition battle. Metsera’s board has declared...
Merck taps Blackstone for $700M ADC push; pays $150M to regain asset
Merck struck parallel transactions that shift financing risk and consolidate control of an ADC program: Blackstone Life Sciences will provide roughly $700 million to underwrite pivotal development...
Off‑the‑shelf CAR‑T shows promise: donor cells deliver deep lymphoma remissions
Caribou reported clinical data suggesting its allogeneic, donor‑derived CAR‑T therapy can induce high response rates in advanced B‑cell lymphoma. Company results showed an overall response rate...
Qiagen buys Parse to scale single‑cell; PacBio partner wins China clearance
Qiagen agreed to acquire Parse Biosciences for $225 million plus up to $55 million in milestones to broaden its foothold in single‑cell sample prep and informatics. Qiagen cited Parse’s...
New lab platforms enter early access: single‑molecule proteomics and Tri‑Mod RNA assay
Nautilus Biotechnology installed its first external single‑molecule protein analysis instrument at the Buck Institute to study tau proteoforms in neurodegenerative disease, marking the company’s...
Doudna spinoff Azalea raises $82M: single‑dose in vivo CAR‑T aims for clinic
Azalea Therapeutics, a spinout from Jennifer Doudna’s lab, launched with an $82 million financing to pursue in‑body genome editing approaches that aim to convert patients’ immune cells into...
Biotech shake‑ups: billionaire‑backed Arena shutters; Colossal buys Viagen cloning arm
Arena BioWorks, a high‑profile, privately funded Boston research institute launched with $500 million, abruptly announced it will shut down operations and lay off staff, citing adverse biotech...
FDA leadership shake-up and uniQure setback: regulator turmoil delays Huntington’s gene therapy
uniQure said the FDA reversed prior guidance and no longer considers Phase I/II data using an external control adequate to support a biologics license application for AMT‑130, its gene therapy for...
Sarepta’s Duchenne confirmatory failure — company to press FDA despite negative readout
Sarepta reported that its ESSENCE Phase III confirmatory trial for two exon‑skipping antisense oligonucleotides failed to meet the primary endpoint, producing a p‑value well above the prespecified...
Metsera takeover battle heats up — Novo raises bid to $10B as Pfizer files lawsuits
Novo Nordisk boosted its takeover offer for obesity biotech Metsera to as much as $10 billion, proposing an initial cash dividend followed by contingent payments tied to development milestones....
Thermo Fisher to buy Clario for $8.8B: clinical trials data and digital push accelerates
Thermo Fisher Scientific agreed to acquire Clario for $8.8 billion to expand its clinical‑trial data, patient‑centric services, and digital capabilities within its Laboratory Products and...
Qiagen buys Parse Biosciences to jump into single‑cell genomics
Qiagen announced it will acquire Parse Biosciences for $225 million upfront plus up to $55 million in milestones, marking a strategic move into scalable single‑cell genomics. Parse’s...
Colossal acquires Viagen Pets & Equine — cloning and biobanks join de‑extinction push
Colossal Biosciences said it has acquired Viagen Pets & Equine, a cloning and reproductive services company that maintains a biobank spanning more than 40 species, including endangered animals....
Doudna‑backed Azalea launches with $82M to pursue single‑dose in‑vivo CAR‑T
Azalea Therapeutics, a spinoff from Jennifer Doudna’s lab, launched with $82 million to develop single‑dose, in‑vivo CAR‑T approaches that convert patients’ immune cells directly inside the body....